journal
Journals Therapeutic Advances in Psycho...

Therapeutic Advances in Psychopharmacology

https://read.qxmd.com/read/39314214/comment-on-attentional-bias-modification-and-attention-control-training-in-ptsd-a-systematic-review-and-meta-analysis
#1
JOURNAL ARTICLE
Coralie Creupelandt, Emilie Veerapa, Arnaud Bugnet, Marielle Wathelet, Alice Demesmaeker, Pierre Grandgenevre, Guillaume Vaiva, Thomas Fovet, Fabien D'Hondt
No abstract text is available yet for this article.
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39314213/incorporation-of-a-specialist-mental-health-clinical-pharmacist-within-a-primary-care-network-patient-referrals-prescribing-decisions-and-clinical-outcomes
#2
JOURNAL ARTICLE
Rebecca Henry, David S Baldwin
BACKGROUND: The benefit of generalist pharmacists working within primary care networks (PCNs) and with general practitioners (GPs) is established. We wished to evaluate the contributions and potential benefits of a specialist mental health care prescribing pharmacist within PCNs. METHOD: We prospectively collected data, on clinical and demographic characteristics, referral sources, interventions, outcomes (objective and subjective), and patient feedback, from 466 completed patients, in one PCN by one specialist mental health pharmacist (working 0...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39295887/geriatric-psychiatry-and-brain-health-in-old-age
#3
EDITORIAL
Rajesh R Tampi, Jordan F Karp
No abstract text is available yet for this article.
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39282238/using-in-silico-methods-to-determine-optimal-tapering-regimens-for-decanoate-based-long-acting-injectable-psychosis-drugs
#4
JOURNAL ARTICLE
James R O'Neill, David M Taylor, Mark A Horowitz
BACKGROUND: Reducing the dose of psychosis drugs in a gradual hyperbolic manner may minimise withdrawal effects and risk of relapse. There is presently limited guidance on tapering decanoate-based long-acting injectable dopamine antagonists (LIDAs). OBJECTIVES: We aimed to apply hyperbolic principles of tapering to the decanoate-based LIDAs flupentixol, zuclopenthixol and haloperidol to develop withdrawal regimens. DESIGN: We used in silico methodology to predict plasma drug levels and D2 occupancy for different LIDA regimens...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39166138/corrigendum-to-comment-on-history-repeating-guidelines-to-address-common-problems-in-psychedelic-science
#5
(no author information available yet)
[This corrects the article DOI: 10.1177/20451253241243242.].
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39132012/exploring-psychedelic-use-in-athletes-and-their-attitudes-toward-psilocybin-assisted-therapy-in-concussion-recovery
#6
JOURNAL ARTICLE
Baeleigh VanderZwaag, Albert Garcia-Romeu, Mauricio A Garcia-Barrera
BACKGROUND: Psychedelics are receiving growing interest among clinical researchers for their effects on mood and cognition. Psilocybin is one of the most widely studied classic psychedelics which has shown good safety and clinical benefit for major depression and substance use disorders. Athletes frequently sustain concussions and often experience myriad symptoms, including cognitive and mood issues, which can persist for weeks or months in 10%-30% of athletes. Psilocybin may be a potential symptom management option for athletes with persisting concussion symptoms...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39091697/long-acting-antipsychotic-treatments-focus-on-women-with-schizophrenia
#7
REVIEW
Sofia Brissos, Vicent Balanzá-Martínez
Effective management of schizophrenia (SZ) requires long-term treatment with antipsychotics (APs) to prevent clinical relapse, attain remission and improve patients' personal and social functioning, and quality of life. Although APs remain the cornerstone treatment for patients with SZ, despite their potential benefits, long-acting injectable APs (LAI-APs) remain underused, most notably in women with SZ. The efficacy and tolerability of APs differ significantly between men and women, and some of these differences are more noticeable depending on the patient's age and the stage of the disorder...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/39070776/sublingual-asenapine-for-agitation-in-malabsorptive-states-three-patient-cases
#8
JOURNAL ARTICLE
Bradley G Burk, Kyle Humphreys, Jim Waites, Bentley Adams, Badari Birur, Pamela E Parker
Gastric malabsorptive conditions may prevent patients from deriving benefit from orally administered medications intended for enteric absorption. While malabsorption is an increasingly common issue, current data on alternative oral options for agitation in these patients are very sparse. Sublingual (SL) asenapine is absorbed transmucosally, bypassing gut absorption, making it a viable consideration. We report on three patients, one with short bowel syndrome, one with viral gastritis, and one with aortic dissection who were trialed on SL asenapine for agitation after failing alternative antipsychotics...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38831918/efficacy-and-safety-of-long-acting-injectable-versus-oral-antipsychotics-in-the-treatment-of-patients-with-early-phase-schizophrenia-spectrum-disorders-a-systematic-review-and-meta-analysis
#9
JOURNAL ARTICLE
Giovanni Vita, Angelantonio Tavella, Giovanni Ostuzzi, Federico Tedeschi, Michele De Prisco, Rafael Segarra, Marco Solmi, Corrado Barbui, Christoph U Correll
BACKGROUND: Long-acting injectable antipsychotics (LAIs) have advantages over oral antipsychotics (OAPs) in preventing relapse and hospitalization in chronically ill patients with schizophrenia-spectrum disorders (SSDs), but evidence in patients with first-episode/recent-onset, that is, early-phase-SSDs is less clear. OBJECTIVES: To assess the relative medium- and long-term efficacy and safety of LAIs versus OAPs in the maintenance treatment of patients with early-phase SSDs...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38827016/metformin-co-commencement-at-time-of-antipsychotic-initiation-for-attenuation-of-weight-gain-a-systematic-review-and-meta-analysis
#10
JOURNAL ARTICLE
Ou Yu, Mengyao Lu, Terence K Y Lai, Margaret Hahn, Sri Mahavir Agarwal, Brian O'Donoghue, Bjørn H Ebdrup, Dan Siskind
BACKGROUND: Antipsychotic medications are associated with weight gain and metabolic derangement. However, comprehensive evidence for the efficacy of co-commenced pharmacological treatments to mitigate initial weight gain is limited. Metformin has been shown to be effective in reducing weight among people on antipsychotic medications who are already overweight, but the potential benefits of metformin co-commencement in mitigating antipsychotic-induced weight gain has not been systematically reviewed...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38827015/the-cardiovascular-safety-of-tricyclic-antidepressants-in-overdose-and-in-clinical-use
#11
REVIEW
David Taylor, Sofia Poulou, Ivana Clark
Tricyclic antidepressants (TCAs) remain widely prescribed for depression and many other conditions. There may be important differences between individual TCA in regard to their overdose toxicity and their cardiac toxicity in clinical use. We conducted a systematic review to compare the toxicity of individual TCA in overdose and the risk of serious adverse cardiac events occurring with therapeutic doses. We used the fatal toxicity index (FTI) and case fatality ratio as markers of fatality in overdose, and hazard ratios or odds ratios for the risk of cardiovascular adverse events during normal clinical use...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38827014/paralytic-ileus-in-a-patient-on-clozapine-therapy-showing-an-inverted-clozapine-norclozapine-ratio-after-switching-valproic-acid-to-carbamazepine-a-case-report
#12
Geke van Weringh, Leonieke van Koolwijk, Lieuwe de Haan, Daan J Touw, Mariken B de Koning
This case report examines the possible correlation between the clozapine/norclozapine ratio and the occurrence of constipation and paralytic ileus. We present the case of a 42-year-old patient diagnosed with schizoaffective disorder undergoing clozapine therapy. Despite intensive treatment with clozapine, haloperidol, valproic acid and biweekly electroconvulsive therapy sessions for over a year, florid psychotic symptoms and fluctuating mood swings persisted. Therefore, valproic acid was replaced by carbamazepine, a potent inducer of several CYP450-enzymes...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38808099/corrigendum-to-semaglutide-for-the-treatment-of-antipsychotic-associated-weight-gain-in-patients-not-responding-to-metformin-a-case-series
#13
(no author information available yet)
[This corrects the article DOI: 10.1177/20451253231165169.].
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38745850/clozapine-induced-cholinergic-urticaria-a-case-report
#14
Nadia El Ouni Amami, Husen Ali-Diabacte, Sarra Ateb, Hamadi Ben Rejeb, Avicenne Bellis, Reza Bellis, Dominique Januel, Noomane Bouaziz
Clozapine, renowned for its efficacy in treatment-resistant schizophrenia, is associated with rare yet potentially severe side effects, including hematological disorders, myocarditis, seizures and gastrointestinal obstruction. Dermatological adverse effects, though less serious, can profoundly impact patients' quality of life. We present the first reported case of cholinergic urticaria induced by clozapine, in a 25-year-old male with treatment-resistant schizophrenia. Four months into clozapine therapy, the patient developed intensely pruritic erythematous lesions triggered by sweating, significantly impairing his daily activities...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38708374/neuroimaging-features-of-cognitive-impairments-in-schizophrenia-and-major-depressive-disorder
#15
REVIEW
Yu-Ting Li, Chi Zhang, Jia-Cheng Han, Yu-Xuan Shang, Zhu-Hong Chen, Guang-Bin Cui, Wen Wang
Cognitive dysfunctions are one of the key symptoms of schizophrenia (SZ) and major depressive disorder (MDD), which exist not only during the onset of diseases but also before the onset, even after the remission of psychiatric symptoms. With the development of neuroimaging techniques, these non-invasive approaches provide valuable insights into the underlying pathogenesis of psychiatric disorders and information of cognitive remediation interventions. This review synthesizes existing neuroimaging studies to examine domains of cognitive impairment, particularly processing speed, memory, attention, and executive function in SZ and MDD patients...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38680419/psychedelic-skepticism-back-to-the-sixties
#16
JOURNAL ARTICLE
Eduardo Ekman Schenberg
No abstract text is available yet for this article.
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38644941/network-analysis-of-the-comorbidity-between-post-traumatic-stress-depression-and-anxiety-symptoms-among-frontline-healthcare-workers-during-the-covid-19-pandemic
#17
JOURNAL ARTICLE
Hui Ouyang, Lili Wu, Wenjie Yan, Keyi Si, Hongli Lv, Jingye Zhan, Jing Wang, Yanpu Jia, Zhilei Shang, Wenfang Chen, Weizhi Liu
BACKGROUND: Coronavirus disease 2019 pandemic pointed out significant mental symptoms of frontline healthcare workers (HCWs). OBJECTIVE: We aimed to estimate the prevalence and comorbidity of post-traumatic stress symptoms (PTSS), depression and anxiety symptoms in HCWs from Fangcang shelter hospitals during the pandemic. DESIGN: Demographic information, post-traumatic stress disorder checklist for DSM-5 (PCL-5), Patient Health Questionnaire (PHQ-9) and Generalized Anxiety Disorder Questionnaire (GAD-7) were obtained online based on stratified random sampling design during April 2022, with 284 eligible responses...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38644940/effect-of-long-acting-antipsychotic-treatment-on-psychiatric-hospitalization-rate-in-early-psychosis-patients-a-naturalistic-study
#18
JOURNAL ARTICLE
Raúl Sancho-Echeverria, Claudia Aymerich, José Manuel Rodríguez-Sánchez, Patxi Gil, Borja Pedruzo, Miguel Ángel González-Torres, Paolo Fusar-Poli, Celso Arango, Ana Catalan
BACKGROUND: The effectiveness of long-acting injectable (LAI) antipsychotics in preventing relapses of first-episode psychosis is currently debated. OBJECTIVES: The study aimed to investigate the number of psychiatric hospitalizations comparing the LAI cohort versus the oral cohort during different phases of the illness, pre-LAI treatment, during LAI treatment, and after LAI treatment. DESIGN: A naturalistic study was conducted on two independent cohorts of early psychosis patients receiving treatment from a specific early intervention service...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38633357/attentional-bias-modification-and-attention-control-training-in-ptsd-a-systematic-review-and-meta-analysis
#19
JOURNAL ARTICLE
Fan Zhang, Chenwei Huang, Wenjie Yan, Hui Ouyang, Weizhi Liu
BACKGROUND: Cognitive models of post-traumatic stress disorder (PTSD) highlighted the effect of maladaptive cognitive processing in the development and maintenance of PTSD. PTSD is related to attentional bias (AB) toward threatening stimuli and greater attentional bias variability (ABV). Attentional bias modification (ABM) and attention control training (ACT) have demonstrated the effect of improving PTSD, but the results of randomized controlled trials (RCTs) are controversial. OBJECTIVES: The current study aimed to evaluate the extent of evidence supporting the efficacy of ABM in the treatment of PTSD...
2024: Therapeutic Advances in Psychopharmacology
https://read.qxmd.com/read/38440104/patient-reported-outcomes-on-sleep-quality-and-circadian-rhythm-during-treatment-with-intravenous-ketamine-for-treatment-resistant-depression
#20
JOURNAL ARTICLE
Raymond Yan, Tyler Marshall, Atul Khullar, Travis Nagle, Jake Knowles, Mai Malkin, Brittany Chubbs, Jennifer Swainson
BACKGROUND: Intravenous (IV) ketamine is a rapid acting antidepressant used primarily for treatment-resistant depression (TRD). It has been suggested that IV ketamine's rapid antidepressant effects may be partially mediated via improved sleep and changes to the circadian rhythm. OBJECTIVES: This study explores IV ketamine's association with changes in patient-reported sleep quality and circadian rhythm in an adult population with TRD. METHODS: Adult patients (18-64 years) with TRD scheduled for IV ketamine treatment were recruited to complete patient rated outcomes measures on sleep quality using the Pittsburgh Sleep Quality Index (PSQI) and circadian rhythm using the Morningness-Eveningness Questionnaire (MEQ)...
2024: Therapeutic Advances in Psychopharmacology
journal
journal
43489
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.